Shenzhen, China, 29 September 2025- MGI Tech Co., Ltd. (“MGI”), a company dedicated to developing core tools and technologies that drive innovation in life sciences, today announced the global trial launch of its HIV-1 full-length sequencing package (“the package”). Developed specifically for the CycloneSEQ nanopore sequencing platform, this new package is designed to overcome critical challenges in analyzing the extreme genetic diversity of the HIV-1 virus.

The high mutation and recombination rates of HIV-1 lead to significant genetic complexity, which accelerates viral evolution. This poses major obstacles for public health, including the rapid development of drug resistance during clinical treatment and hindering the creation of a broadly effective preventive vaccine due to insufficient cross-immunity between subtypes.

MGI's HIV-1 Full-Length Genome Sequencing Package directly addresses these challenges by providing researchers with a powerful tool for comprehensive genomic analysis. Key advantages include:

• Accurate Genetic Analysis: Powered by the CycloneSEQ sequencing platform, the package achieves full coverage of the nearly 9.7 kb HIV-1 genome. This enables accurate identification of low-frequency quasispecies and structural variations, avoiding assembly errors caused by complex repeat sequences or recombination events.
• Simplified Library Preparation: Library preparation is simplified through a unique protocol that allows for simultaneous reverse transcription of the 5' and 3' genome ends in a single tube, enhancing both efficiency and reliability.
• Advanced, Integrated Bioinformatics: The package includes a self-developed analysis software, which supports full-length assembly of the HIV-1 genome, precise subtyping, superinfection analysis, quasispecies identification, and drug resistance annotation. It also allows for hybrid assembly of sequencing data from CycloneSEQ and DNBSEQ platforms.

By integrating a simplified experimental workflow with the robust CycloneSEQ platform, this package provides a streamlined solution for decoding the complex HIV-1 genome. It is expected to significantly contribute to advancements in precise AIDS treatment, accurate transmission chain tracing, and vaccine research.

To apply for a trail of HI1-V full-length genome sequencing package, please contact MGI sales in your area for details.

About MGI

MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various other industries.

Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and establishing research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future.

For more information, please visit https://en.mgi-tech.com/, LinkedIn, X, and YouTube.